Bluestone Trials

Mindfulness-Based Stress Reduction To Improve Cognitive Function During Aromatase Inhibitor Therapy

Improving Brain Health During Breast Cancer Therapy
Status: Currently recruiting subjects.

Brief Description: If you are a postmenopausal woman who was diagnosed with breast cancer, you may qualify for this research study. The purpose of this study is to learn whether Mindfulness-Based Stress Reduction or a Health Enhancement Program improves cognitive function (your ability to concentrate and remember things) for women who take aromatase inhibitors. This study will evaluate cognitive function using a brain imaging technique called Magnetic Resonance Imaging (MRI), cognitive tests, and questionnaires. You will be paid up to $250 for completing the study.

Inclusion Criteria:

1. Have gone through menopause (are postmenopausal)

2. Are younger than 80 years of age

3. Are diagnosed with stage 0 (DCIS) or stage 1, 2, or 3 breast cancer

4. Are taking an aromatase inhibitor or will be starting it soon

 

Exclusion Criteria:

1. No stage IV (metastatic) breast cancer

2. Not claustrophobic (afraid of being in an MRI machine)

3. No major psychiatric disorder (schizophrenia, bipolar I disorder); no neurological disorder (Parkinson's Disease, dementia); and no head trauma.



Interested in participating?

If you, a family member, or someone you know is interested in this study, please contact our clinical research coordinator Makeda Brown at 212-998-9202 or makeda.culley@nyu.edu. Or, fill out our contact form. We will get back to you as soon as possible. Confidentiality will be maintained for all applicants and participants.